Innate goes it alone on a cancer drug, buying out Novo for up to $30M

France's Innate Pharma has signed a deal to pay Novo Nordisk ($NVO) $2.7 million up front and as much as $27 million in milestones for exclusive rights to the pair's Phase II-ready cancer immunotherapy. Under the agreement, Innate gets IPH2201--a drug that blocks the checkpoint receptor NKG2A to spur cancer cell death--developed through a multiyear research collaboration between the two. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.